Edward Anderson, PA
Physician Assistant · Granite City, ILNPI 1326104910
Payments from drug & device makers
Across 294 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$580
- Lilly USA, LLC$526
- Novo Nordisk$483
- Amgen$339
- Pfizer$307
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $1,053 |
| AstraZeneca | 27 | $580 |
| Lilly USA, LLC | 33 | $526 |
| Novo Nordisk | 33 | $483 |
| Amgen | 21 | $339 |
| Pfizer | 20 | $307 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $205 |
| Lundbeck LLC | 8 | $143 |
| Neurocrine Biosciences, Inc. | 8 | $126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $121 |
| Abbott | 5 | $103 |
| Exact Sciences | 6 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Boehringer Ingelheim | 4 | $69 |
| Verity Pharmaceuticals Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Novartis | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| GSK | 3 | $54 |
| Merck | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Alkermes, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $28 |
| Johnson & Johnson | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Vertex | 1 | $19 |
| Corium, LLC | 1 | $16 |
| Viiv Healthcare Company | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,901 in reported general payments places this provider in the 90th percentile of 3,912 physician assistant providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $92,241 |
| LinzessLinaclotide | 65 | $44,169 |
| JanuviaSitagliptin Phosphate | 45 | $41,657 |
| EliquisApixaban | 41 | $40,645 |
| FarxigaDapagliflozin Propanediol | 45 | $38,516 |
| JardianceEmpagliflozin | 27 | $33,398 |
| MounjaroTirzepatide | 29 | $30,973 |
| RybelsusSemaglutide | 27 | $27,831 |
| RexultiBrexpiprazole | 15 | $23,041 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,758 |
| TrulicityDulaglutide | 25 | $22,514 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $16,602 |
| XareltoRivaroxaban | 22 | $14,910 |
| MyrbetriqMirabegron | 11 | $11,253 |
| Emgality PenGalcanezumab-Gnlm | 14 | $10,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $483 | $120,07294 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $580 | $64,265103 claims |
| Lilly USA, LLCMounjaro, Trulicity | $526 | $53,48754 claims |
| AbbVieLinzess, Synthroid | $1,053 | $45,72179 claims |
| MerckJanuvia | $35 | $41,65745 claims |
| PfizerEliquis | $307 | $40,64541 claims |
| Boehringer IngelheimJardiance, Tradjenta | $69 | $39,44538 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $65 | $23,04115 claims |
| Johnson & JohnsonXarelto | $22 | $14,91022 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $11,25311 claims |
| GSKBreo Ellipta | $54 | $5,08813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,912 physician assistant providers in Illinois.
Other physician assistant in Granite City
- Andrew MastroChicago$419K
- Christopher AricoSkokie$407K
- Karlijn BurridgeWestmont$144K
- Ian MackeySkokie$135K
- Stephanie TraceyItasca$122K
- Olabimpe PhilipsAddison$103K
- Renata BlockChicago$103K
- Margaret RomanoChicago$82K
- Christina StarksChicago$77K
- Darrel CutlerHerrin$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.